; (iii) individuals with disabilities; (iv) homeless individuals; (v) newly resettled refugees; and (vi) individuals in rural communities. (B) High-risk facilities, including— (i) long-term care facilities; (ii) group homes; and (iii) jails and prisons. (5) A description of any deviations from Federal distribution plans, including issues relating to the following: (A) Sites administering large numbers of COVID–19 vaccines, such as pharmacy chain stores, schools, and primary health care providers. (B) Tracking procedures for COVID–19 vaccines, particularly in areas of greatest need. (C) Outreach to health care providers and the public about the availability, benefits, safety, contraindications, and costs of receiving COVID–19 vaccines. (D) Outreach to health care providers regarding the responsibilities of such providers to track vaccine administration and monitor adverse events. (E) Uniform record keeping relating to the administration of COVID–19 vaccines (including Federal support for State and local immunization information systems). (F) Overuse or gaps in treatment. (c) Briefings On each date on which the Secretary submits to Congress a report under subsection (a), the Secretary shall be available to brief Congress on the contents of such report. (d) Termination This section shall cease to have effect on the date that is 18 months after the date on which the initial report is submitted to Congress under subsection (a). (e) State defined In this section, the term State means each of the several States, the District of Columbia, each commonwealth, territory, or possession of the United States, and each federally recognized Indian Tribe.